Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EPS (Basic) (2016 - 2025)

Sunshine Biopharma's EPS (Basic) history spans 14 years, with the latest figure at -$0.46 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 107.31% year-over-year to -$0.46; the TTM value through Dec 2025 reached -$1.48, up 77.54%, while the annual FY2025 figure was -$1.44, 80.33% up from the prior year.
  • EPS (Basic) reached -$0.46 in Q4 2025 per SBFM's latest filing, down from -$0.19 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $6.29 in Q4 2024 to a low of -$85.65 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$11.49, with a median of -$1.08 recorded in 2021.
  • Peak YoY movement for EPS (Basic): soared 135.66% in 2021, then crashed 237133.33% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at $0.97 in 2021, then plummeted by 259.67% to -$1.55 in 2022, then tumbled by 5430.04% to -$85.65 in 2023, then soared by 107.34% to $6.29 in 2024, then crashed by 107.31% to -$0.46 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EPS (Basic) are -$0.46 (Q4 2025), -$0.19 (Q3 2025), and -$0.39 (Q2 2025).